Compare Enphase Energy Inc (ENPH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Novo Nordisk A/S — how do they compare? Enphase Energy Inc trades at $32.81 (market cap $4.35B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 38× Enphase Energy Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Novo Nordisk A/S for 116 Days on average.
| ENPH | NVO | |
|---|---|---|
Market Cap | $4.35B | $165.31B |
Volume | 5,068,595 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $72.33 | $63.98 |
52-Week Low | $26.12 | $35.29 |
Typical Hold Time | 72 Days | 116 Days |
Enterprise Value | $3.99B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.91, down 1.76% amid bearish technical signals and mixed earnings performance. The stock faces headwinds from solar sector volatility but maintains solid fundamentals with 46.95% gross margins and positive cash flow. Recent developments include IQ Meter Collar utility approvals and solid-state transformer advancements for AI data centers, providing potential growth catalysts despite recent earnings misses.
The outlook remains cautious with analyst consensus at $42.90 offering 30% upside potential, though technical indicators suggest near-term pressure. Key risks include solar industry financing challenges and competitive threats, while institutional sentiment shows modest optimism with 42% buy ratings. The stock presents a growth opportunity for investors comfortable with sector volatility and execution risks.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
